Table 3

Results of AmpC hyperproduction complementation studies in PBLR strainsa

StrainbResistance mutation(s)PlasmidMIC (μg/ml)ampC expressionc
ampDdacBCAZFEPPTZATMIMPMERTOL
PAO1WTWT214420.50.51
pUCPAD214420.50.5ND
pUCPADE114420.50.5ND
PAΔampDΔampDWT84328220.548
pUCPAD112220.50.51.5
pUCPADE111220.50.51.3
PAΔdacBWTΔdacB328641620.5134
pUCPAD844220.5127
pUCPADE112210.50.52.5
PAΔampD dacBΔampDΔdacB648256642221,859
pUCPAD1686416211460
pUCPADE414810.515.2
3F4D28GG427D25632256512323242,112
pUCPAD12832128643232264
pUCPADE168321616413.8
3D8WTG366S; A394P12832256256323241,351
pUCPAD1616323232162504
pUCPADE44832216152
2A1Ins. 1 bp (C) in 481T428P25664256128323241,722
pUCPAD328643232162419
pUCPADE448161616156
1C5Q155XWT328646432321317
pUCPAD4832323232111
pUCPADE481616163214.5
2I4ΔampDEM200I; del D20112832256128321641,438
pUCPAD16832161681466
pUCPADE248488119
3F5V10GWT161664163216167
pUCPAD16166416328114
pUCPADE448832412.1
  • a Abbreviations are the same as in Table 2. ND, not determined.

  • b PAO1 ampD (PAΔampD), dacB (PAΔdacB), and ampD-dacB (PAΔampD dacB) knockout mutants generated in a previous work (24) were used as controls.

  • c Relative mRNA expression compared to that of wild-type PAO1.